Displaying drugs 10326 - 10350 of 12422 in total
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … that promotes growth and production of blood platelets. ... SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor ... used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of …
(S)-acetoin
A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Experimental
Matched Description: … A product of fermentation. It is a component of the butanediol cycle in microorganisms. …
(R)-acetoin
A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
Experimental
Matched Description: … A product of fermentation. It is a component of the butanediol cycle in microorganisms. …
Sevuparin
Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).
Investigational
Matched Description: … Subcutaneous Doses of Sevuparin). ... investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of …
Seliforant
Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).
Investigational
Matched Description: … Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 …
Pexiganan
Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).
Investigational
Matched Description: … Mild Infections of Diabetic Foot Ulcers). ... under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of …
Betula pendula tar oil
Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation and it...
Nutraceutical
Matched Description: … Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. ... [T219] The utilization of this product started during the second world war in the Sovietic Union. ... [L2862] Under the EMA, betula pendula tar oil is approved under the category of herbal medicines for …
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Description: … of fluid in the eye, is believed to be one of the principal causes of glaucoma. ... The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount ... PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of …
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Matched Description: … 7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes ... the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. …
Camrelizumab
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Investigational
Matched Description: … ED-SCLC After Failure of First Line Standard Therapy). ... is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of …
RSV-604
RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Investigational
Matched Description: … Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.). ... is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of …
Foralumab
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Investigational
Matched Description: … Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab …
Tilsotolimod
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Investigational
Matched Description: … With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)). ... Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination …
Cyamemazine
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Description: … class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. ... Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine ... actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of …
2-Hydroxyestradiol
2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol.
Experimental
Matched Description: … It is also a positional isomer of estriol. [A31630] ... 2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol …
Modithromycin
Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia).
Investigational
Matched Description: … Another Antibiotic in the Treatment of Community Acquired Pneumonia). ... Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus …
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
Etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID- …
ADH-1
Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models. At the end of 2006, the...
Investigational
Matched Description: … Phase II trials of ADH-1. ... ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors ... causing angiolysis (disruption of blood vessels) and tumor damage. …
N-(2-Aminoethyl)-1-aziridineethanamine
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Sisunatovir
Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Investigational
Matched Description: … Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of …
Opiranserin
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty). ... Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of …
Rilzabrutinib
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Matched Description: … for the treatment of immune disorders, such as immune thrombocytopenic purpura. ... Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated …
Displaying drugs 10326 - 10350 of 12422 in total